<?xml version='1.0' encoding='utf-8'?>
<document id="15289793"><sentence text="Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine."><entity charOffset="0-12" id="DDI-PubMed.15289793.s1.e0" text="Rosuvastatin" /><entity charOffset="109-121" id="DDI-PubMed.15289793.s1.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.15289793.s1.e0" e2="DDI-PubMed.15289793.s1.e0" /><pair ddi="false" e1="DDI-PubMed.15289793.s1.e0" e2="DDI-PubMed.15289793.s1.e1" /></sentence><sentence text="Cyclosporine (INN, ciclosporin) increases the systemic exposure of all statins"><entity charOffset="0-12" id="DDI-PubMed.15289793.s2.e0" text="Cyclosporine" /><entity charOffset="19-30" id="DDI-PubMed.15289793.s2.e1" text="ciclosporin" /><pair ddi="false" e1="DDI-PubMed.15289793.s2.e0" e2="DDI-PubMed.15289793.s2.e0" /><pair ddi="false" e1="DDI-PubMed.15289793.s2.e0" e2="DDI-PubMed.15289793.s2.e1" /></sentence><sentence text=" Therefore rosuvastatin pharmacokinetic parameters were assessed in an open-label trial involving stable heart transplant recipients (&gt; or =6 months after transplant) on an antirejection regimen including cyclosporine"><entity charOffset="11-23" id="DDI-PubMed.15289793.s3.e0" text="rosuvastatin" /><entity charOffset="205-217" id="DDI-PubMed.15289793.s3.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.15289793.s3.e0" e2="DDI-PubMed.15289793.s3.e0" /><pair ddi="false" e1="DDI-PubMed.15289793.s3.e0" e2="DDI-PubMed.15289793.s3.e1" /></sentence><sentence text=" Rosuvastatin has been shown to be a substrate for the human liver transporter organic anion transporting polypeptide C (OATP-C)"><entity charOffset="1-13" id="DDI-PubMed.15289793.s4.e0" text="Rosuvastatin" /></sentence><sentence text=" Inhibition of this transporter could increase plasma concentrations of rosuvastatin"><entity charOffset="72-84" id="DDI-PubMed.15289793.s5.e0" text="rosuvastatin" /></sentence><sentence text=" Therefore the effect of cyclosporine on rosuvastatin uptake by cells expressing OATP-C was also examined"><entity charOffset="25-37" id="DDI-PubMed.15289793.s6.e0" text="cyclosporine" /><entity charOffset="41-53" id="DDI-PubMed.15289793.s6.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.15289793.s6.e0" e2="DDI-PubMed.15289793.s6.e0" /><pair ddi="false" e1="DDI-PubMed.15289793.s6.e0" e2="DDI-PubMed.15289793.s6.e1" /></sentence><sentence text="" /><sentence text="Ten subjects were assessed while taking 10 mg rosuvastatin for 10 days; 5 of these were then assessed while taking 20 mg rosuvastatin for 10 days"><entity charOffset="46-58" id="DDI-PubMed.15289793.s8.e0" text="rosuvastatin" /><entity charOffset="121-133" id="DDI-PubMed.15289793.s8.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.15289793.s8.e0" e2="DDI-PubMed.15289793.s8.e0" /><pair ddi="false" e1="DDI-PubMed.15289793.s8.e0" e2="DDI-PubMed.15289793.s8.e1" /></sentence><sentence text=" Rosuvastatin steady-state area under the plasma concentration-time curve from time 0 to 24 hours [AUC(0-24)] and maximum observed plasma concentration (Cmax) were compared with values in controls (historical data from 21 healthy volunteers taking 10 mg rosuvastatin)"><entity charOffset="1-13" id="DDI-PubMed.15289793.s9.e0" text="Rosuvastatin" /><entity charOffset="254-266" id="DDI-PubMed.15289793.s9.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.15289793.s9.e0" e2="DDI-PubMed.15289793.s9.e0" /><pair ddi="false" e1="DDI-PubMed.15289793.s9.e0" e2="DDI-PubMed.15289793.s9.e1" /></sentence><sentence text=" Rosuvastatin uptake by OATP-C-transfected Xenopus oocytes was also studied by use of radiolabeled rosuvastatin with and without cyclosporine"><entity charOffset="1-13" id="DDI-PubMed.15289793.s10.e0" text="Rosuvastatin" /><entity charOffset="99-111" id="DDI-PubMed.15289793.s10.e1" text="rosuvastatin" /><entity charOffset="129-141" id="DDI-PubMed.15289793.s10.e2" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.15289793.s10.e0" e2="DDI-PubMed.15289793.s10.e0" /><pair ddi="false" e1="DDI-PubMed.15289793.s10.e0" e2="DDI-PubMed.15289793.s10.e1" /><pair ddi="false" e1="DDI-PubMed.15289793.s10.e0" e2="DDI-PubMed.15289793.s10.e2" /><pair ddi="false" e1="DDI-PubMed.15289793.s10.e1" e2="DDI-PubMed.15289793.s10.e1" /><pair ddi="false" e1="DDI-PubMed.15289793.s10.e1" e2="DDI-PubMed.15289793.s10.e2" /></sentence><sentence text="" /><sentence text="In transplant recipients taking 10 mg rosuvastatin, geometric mean values and percent coefficient of variation for steady-state AUC(0-24) and Cmax were 284 ng"><entity charOffset="38-50" id="DDI-PubMed.15289793.s12.e0" text="rosuvastatin" /></sentence><sentence text=" h/mL (31" /><sentence text="3%) and 48" /><sentence text="7 ng/mL (47" /><sentence text="2%), respectively" /><sentence text=" In controls, these values were 40" /><sentence text="1 ng" /><sentence text=" h/mL (39" /><sentence text="4%) and 4" /><sentence text="58 ng/mL (46" /><sentence text="9%), respectively" /><sentence text=" Compared with control values, AUC(0-24) and Cmax were increased 7" /><sentence text="1-fold and 10" /><sentence text="6-fold, respectively, in transplant recipients" /><sentence text=" In transplant recipients taking 20 mg rosuvastatin, these parameters increased less than dose-proportionally"><entity charOffset="39-51" id="DDI-PubMed.15289793.s26.e0" text="rosuvastatin" /></sentence><sentence text=" Rosuvastatin had no effect on cyclosporine blood concentrations"><entity charOffset="1-13" id="DDI-PubMed.15289793.s27.e0" text="Rosuvastatin" /><entity charOffset="31-43" id="DDI-PubMed.15289793.s27.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.15289793.s27.e0" e2="DDI-PubMed.15289793.s27.e0" /><pair ddi="false" e1="DDI-PubMed.15289793.s27.e0" e2="DDI-PubMed.15289793.s27.e1" /></sentence><sentence text=" The in vitro results demonstrate that rosuvastatin is a good substrate for OATP-C-mediated hepatic uptake (association constant, 8"><entity charOffset="39-51" id="DDI-PubMed.15289793.s28.e0" text="rosuvastatin" /></sentence><sentence text="5 +/- 1" /><sentence text="1 micromol/L) and that cyclosporine is an effective inhibitor of this process (50% inhibition constant, 2"><entity charOffset="23-35" id="DDI-PubMed.15289793.s30.e0" text="cyclosporine" /></sentence><sentence text="2 +/- 0" /><sentence text="4 micromol/L when the rosuvastatin concentration was 5 micromol/L)"><entity charOffset="0-10" id="DDI-PubMed.15289793.s32.e0" text="4 micromol" /><entity charOffset="22-34" id="DDI-PubMed.15289793.s32.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.15289793.s32.e0" e2="DDI-PubMed.15289793.s32.e0" /><pair ddi="false" e1="DDI-PubMed.15289793.s32.e0" e2="DDI-PubMed.15289793.s32.e1" /></sentence><sentence text="" /><sentence text="Rosuvastatin exposure was significantly increased in transplant recipients on an antirejection regimen including cyclosporine"><entity charOffset="0-12" id="DDI-PubMed.15289793.s34.e0" text="Rosuvastatin" /><entity charOffset="113-125" id="DDI-PubMed.15289793.s34.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.15289793.s34.e0" e2="DDI-PubMed.15289793.s34.e0" /><pair ddi="false" e1="DDI-PubMed.15289793.s34.e0" e2="DDI-PubMed.15289793.s34.e1" /></sentence><sentence text=" Cyclosporine inhibition of OATP-C-mediated rosuvastatin hepatic uptake may be the mechanism of the drug-drug interaction"><entity charOffset="1-13" id="DDI-PubMed.15289793.s35.e0" text="Cyclosporine" /><entity charOffset="44-56" id="DDI-PubMed.15289793.s35.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.15289793.s35.e0" e2="DDI-PubMed.15289793.s35.e0" /><pair ddi="false" e1="DDI-PubMed.15289793.s35.e0" e2="DDI-PubMed.15289793.s35.e1" /></sentence><sentence text=" Coadministration of rosuvastatin with cyclosporine needs to be undertaken with caution"><entity charOffset="21-33" id="DDI-PubMed.15289793.s36.e0" text="rosuvastatin" /><entity charOffset="39-51" id="DDI-PubMed.15289793.s36.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.15289793.s36.e0" e2="DDI-PubMed.15289793.s36.e0" /><pair ddi="false" e1="DDI-PubMed.15289793.s36.e0" e2="DDI-PubMed.15289793.s36.e1" /></sentence><sentence text="" /></document>